Monitoring heart health during HER2 therapy for breast cancer
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is stage 1, 2, or 3 (it has not spread to other parts of your body).
- You are between 18 and 79 years old.
- Your cancer is HER2-positive, meaning it has a specific protein that can be targeted by treatments like Herceptin, and you are scheduled to receive that treatment.
- You have no current or past serious heart problems (like heart failure, heart attack, or an irregular heartbeat).
- You have not received more than a certain amount of a strong chemotherapy drug called anthracycline (like doxorubicin) before starting your targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a method to predict and warn about heart damage from a common type of breast cancer chemotherapy. If you have HER2-positive breast cancer and will receive anthracycline drugs, this trial may help monitor your heart health.
This trial studies whether it’s safe to continue HER2-targeted breast cancer treatment (like trastuzumab, pertuzumab, or T-DM1) even when heart function (left ventricle) is reduced. It may help people avoid stopping a helpful cancer medicine because of heart concerns.
This study looks at how breast cancer medicines affect the heart. It may help doctors better prevent, spot early, and manage heart side effects from trastuzumab and/or anthracycline chemotherapy.
This trial is checking if a simple blood test (NT-proBNP) can help spot early signs of heart side effects from certain breast cancer treatments (chemotherapy plus HER2 blockers). If successful, it might help doctors adjust treatment sooner to protect your heart.
This study grows heart muscle cells from your blood or skin to better understand why some people develop heart problems from HER2 cancer treatments. You may be helping researchers learn how to predict and prevent treatment-related heart damage.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
Hear when a new Cardiovascular Health trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.